Lisa N DrakemanLisa N. Drakeman was the founding CEO of one of Europe's most successful biotechnology companies. Under her leadership, the company set numerous financing records, including a record setting IPO, and inaugurated research programs leading to the new FA-approved medicines DARZALEX (multiple myeloma) and KESIMPTA (multiple sclerosis). She is a member of the board of the Medical University of South Carolina Foundation for Research Development. She has received numerous industry honors, including the Sol J. Barer Award for Vision, Innovation, and Leadership. She has been a faculty member at Princeton University and regularly lectures on entrepreneurship at universities in the US and Europe. She received a PhD from Princeton University. Read More Read Less